Intranasal Dexmedetomidine or Esketamine for Negative Postoperative Behavioral Changes in Children

Official title

Exploring the Association of Perioperative Electroencephalographic Changes Following Preoperative Intranasal Dexmedetomidine or Esketamine With Negative Postoperative Behavioral Changes in Children Undergoing Day Surgery

Overview

The goal of this clinical trial is to learn whether intranasal dexmedetomidine or esketamine given before anesthesia can reduce negative postoperative behavioral changes in children undergoing day surgery. Negative postoperative behavioral changes may include anxiety, sleep problems, nightmares, irritability, or other unusual behaviors after surgery. This study will also examine whether changes in brain wave patterns during the perioperative period are related to these behavioral changes. The main questions this study aims to answer are: Does intranasal dexmedetomidine reduce negative postoperative behavioral changes in children after day surgery? Does intranasal esketamine reduce negative postoperative behavioral changes in children after day surgery? Are perioperative electroencephalographic (EEG) features associated with negative postoperative behavioral changes? Researchers will compare intranasal dexmedetomidine, intranasal esketamine, and normal saline to see whether these treatments differ in their effects on postoperative behavior and perioperative EEG features. Participants will be randomly assigned to receive intranasal dexmedetomidine, intranasal esketamine, or intranasal normal saline about 30 minutes before anesthesia. They will receive routine perioperative monitoring, including EEG monitoring during surgery and recovery. They will also be assessed for sedation, pain, and emergence delirium. Follow-up assessments of postoperative behavioral changes will be completed on postoperative days 3, 7, and 28.

Detailed description

This multicenter, prospective, randomized, double-blind, controlled clinical trial will evaluate whether preoperative intranasal dexmedetomidine or esketamine can reduce negative postoperative behavioral changes in children undergoing day surgery under general anesthesia. The study will also explore whether perioperative electroencephalographic (EEG) features are associated with these behavioral changes and may help explain the effects of the study drugs.

A total of 342 children undergoing elective day surgery will be enrolled across four centers. Eligible participants will be randomly assigned in a 1:1:1 ratio to receive intranasal dexmedetomidine 2.0 micrograms/kg, intranasal esketamine 1.0 mg/kg, or an equal volume of normal saline approximately 30 minutes before induction of anesthesia. Study medications will be prepared in identical, unlabeled nasal spray devices to maintain blinding. Participants, investigators, and outcome assessors will remain unaware of treatment assignment throughout the study.

After study drug administration, participants will undergo routine perioperative monitoring. Sedation will be assessed before surgery. During anesthesia and recovery, EEG and other perioperative clinical data will be collected. Postoperative assessments will include pain and emergence delirium. Negative postoperative behavioral changes will be evaluated on postoperative days 3, 7, and 28. The primary outcome is the incidence of negative postoperative behavioral changes on postoperative day 7. Secondary analyses will assess behavioral outcomes at postoperative days 3 and 28 and examine the relationship between perioperative EEG patterns and postoperative behavioral changes.

This study is designed to provide evidence on the comparative effects of intranasal dexmedetomidine and esketamine on postoperative behavioral recovery in children undergoing day surgery and to identify perioperative EEG markers that may be associated with adverse behavioral outcomes.

Interventions

• Drug Dexmedetomidine
  Intranasal dexmedetomidine 2.0 micrograms/kg administered once approximately 30 minutes before induction of general anesthesia.
• Drug Esketamine
  Intranasal esketamine 1.0 mg/kg administered once approximately 30 minutes before induction of general anesthesia.
• Drug Normal Saline
  Intranasal normal saline of equal volume administered once approximately 30 minutes before induction of general anesthesia.

Primary outcome measures

• Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 7 [Time frame: Postoperative Day 7]

Secondary outcome measures (2)

• Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 3 [Time frame: Postoperative Day 3]
• Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 28 [Time frame: Postoperative Day 28]

Eligibility criteria

Inclusion criteria

• Children aged 2 to 12 years.
• Scheduled to undergo elective day surgery under general anesthesia.
• ASA (American Society of Anesthesiologists) physical status I to III.

Exclusion criteria

• Congenital diseases or severe liver or kidney dysfunction.
• History of allergic reactions to study drugs.
• Neuromuscular diseases, cerebral palsy, epilepsy.
• Other psychiatric or neurological disorders.
• Body mass index (BMI) ≥ 30 kg/m².
• Severe upper respiratory tract infections prior to surgery.
• Use of sedatives or analgesics within 48 hours before surgery.
• Exposure to major life stressors within 1 month before surgery (e.g., family separation, death of a parent).
• Refusal to participate or failure to obtain consent from the child's legal guardian.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Double blind

Primary purpose

Treatment

Study locations

China · 1 center

• Children's Hospital of Nanjing Medical University — Nanjing

Identifiers

NCT: NCT07570160 · 202512066-2 · SWYY2025002065

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗